Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
GenMark Diagnostics, Inc. (GNMK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/25/2021 |
8-K
| Quarterly results |
| 10/28/2020 |
8-K
| Quarterly results |
| 08/04/2020 |
8-K
| Quarterly results |
| 05/04/2020 |
8-K
| Quarterly results |
| 03/02/2020 |
8-K
| Quarterly results |
| 11/06/2019 |
8-K
| Quarterly results |
| 08/05/2019 |
8-K
| Quarterly results |
| 04/30/2019 |
8-K
| Quarterly results |
| 02/21/2019 |
8-K
| Quarterly results |
| 10/29/2018 |
8-K
| Quarterly results |
| 07/30/2018 |
8-K
| Quarterly results |
| 05/01/2018 |
8-K
| Quarterly results |
| 02/27/2018 |
8-K
| Quarterly results |
| 11/02/2017 |
8-K
| Quarterly results |
| 08/01/2017 |
8-K
| Quarterly results |
| 05/02/2017 |
8-K
| Form 8-K - Current report |
| 02/28/2017 |
8-K
| Form 8-K - Current report |
| 11/03/2016 |
8-K
| Quarterly results |
| 07/28/2016 |
8-K
| Quarterly results |
| 05/03/2016 |
8-K
| Form 8-K - Current report |
| 02/23/2016 |
8-K
| Quarterly results|
Docs:
|
"GenMark Reports Fourth Quarter and Full Year 2015 Results Fourth Quarter Revenue increased 34% Versus Prior Year to $13.2 million Fourth Quarter Gross Margin Increased to 64%, and XT-8 Installed Base Grew by 17 to 633 ePlex Production Capacity Increased to Support Upcoming European Launch Additional Time Likely Required to Address Remaining ePlex Manufacturing Variability CARLSBAD, Calif.-- GenMark Diagnostics, Inc. , a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2015. Revenue for the fourth quarter of 2015 was $13.2 million, an increase of 34% over the prior year period. Full year 2015 revenue grew to $39.4 million, an increase of 29% versus 2014. During the quarter, 17 ..." |
|
| 10/27/2015 |
8-K
| Quarterly results|
Docs:
|
"GenMark Diagnostics Reports Q3 Financial Results Third Quarter Revenue of $8.5 Million, Up 34% Versus Prior Year XT-8 Installed Base Expanded by 25 to 616 European ePlex™ Launch Now Expected in the First Quarter of 2016 External ePlex Studies Recently Commenced at the First Customer Site CARLSBAD, Calif.-- GenMark Diagnostics, Inc. , a leading provider of automated, multiplex molecular diagnostic testing systems, today reported third quarter 2015 financial results. Revenue for the third quarter of 2015 was $8.5 million, an increase of 34% over the prior year period. During the quarter, 25 additional XT-8 analyzers were placed in end-user laboratories, resulting in a total installed base of 616 analyzers within the U.S. market. Gross profit for the third quarter was $5.1 million, or 6..." |
|
| 08/06/2015 |
8-K
| Quarterly results |
| 05/05/2015 |
8-K
| Quarterly results|
Docs:
|
"GenMark Diagnostics Reports Q1 Financial Results First Quarter Revenue of $10.1 Million, Up 28% Versus Prior Year XT-8 Installed Base Expanded by 22 to 562 European ePlex™ Launch on Track for Fourth Quarter 2015 Full Year Revenue Guidance Maintained at $38-40 Million CARLSBAD, Calif.-- GenMark Diagnostics, Inc. , a leading provider of automated, multiplex molecular diagnostic testing systems, today reported first quarter 2015 financial results. As previously reported, revenue for the first quarter of 2015 was $10.1 million, an increase of 28% over the prior year period. During the quarter, 22 additional XT-8 analyzers were placed in end-user laboratories, resulting in a total installed base of 562 analyzers within the U.S. market. Gross profit for the first quarter was $6.1 million, ..." |
|
| 02/24/2015 |
8-K
| Quarterly results|
Docs:
|
"GenMark Reports Fourth Quarter and Full Year 2014 Results Fourth Quarter Revenue $9.8 million, Up 52% Versus Prior Year Gross Margin Increases to 61% in the Fourth Quarter ePlex™ European Launch on Track for Mid-Year CARLSBAD, Calif.-- GenMark Diagnostics, Inc. , a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2014. Revenue for the fourth quarter of 2014 was $9.8 million, an increase of 52% over the prior year period. Full year 2014 revenue grew to $30.6 million, an increase of 59% versus 2013 base business revenue, which excludes revenues from former customer NMTC. During the quarter, 38 additional XT-8 analyzers were placed in end-user laboratories, resulting in a t..." |
|
| 10/30/2014 |
8-K
| Quarterly results |
| 08/11/2014 |
8-K
| Quarterly results |
| 05/06/2014 |
8-K
| Quarterly results |
| 03/11/2014 |
8-K
| Quarterly results |
| 11/12/2013 |
8-K
| Form 8-K - Current report |
| 08/07/2013 |
8-K
| Form 8-K - Current report |
| 05/08/2013 |
8-K
| Form 8-K - Current report |
| 03/12/2013 |
8-K
| Quarterly results |
| 11/08/2012 |
8-K
| Form 8-K - Current report |
|
|
|